| Document and Entity Information - USD ($) | 12 Months Ended | |
| Jun. 30, 2017 | Dec. 31, 2016 | |
| Document and Entity Information: | ||
| Entity Registrant Name | SANGUI BIOTECH INTERNATIONAL INC | |
| Document Type | 10-K | |
| Document Period End Date | Jun. 30, 2017 | |
| Trading Symbol | sgbi | |
| Amendment Flag | false | |
| Entity Central Index Key | 1,104,280 | |
| Current Fiscal Year End Date | --06-30 | |
| Entity Common Stock, Shares Outstanding | 187,261,503 | |
| Entity Public Float | $ 181,761,503 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Current Reporting Status | No | |
| Entity Voluntary Filers | No | |
| Entity Well-known Seasoned Issuer | No | |
| Document Fiscal Year Focus | 2,017 | |
| Document Fiscal Period Focus | FY |
| Consolidated Balance Sheets - USD ($) | Jun. 30, 2017 | Jun. 30, 2016 |
| CURRENT ASSETS | ||
| Cash | $ 56,990 | $ 70,074 |
| Prepaid expenses and other assets | 26,662 | 30,292 |
| Tax refunds receivable | 3,183 | 4,070 |
| Accounts receivable, net | 468 | 504 |
| Note receivable - related party | 6,470 | 5,479 |
| Total Current Assets | 93,773 | 110,419 |
| TOTAL ASSETS | 93,773 | 110,419 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | 188,855 | 200,446 |
| Related party payables | 12,214 | 8,445 |
| Note payable | 39,118 | 38,154 |
| Notes payable - related party | 114,109 | 110,940 |
| Total Current Liabilities | 354,296 | 357,985 |
| STOCKHOLDERS' EQUITY (Deficit) | ||
| Common stock | 32,709,868 | 32,392,657 |
| Additional paid-in capital | 4,513,328 | 4,513,328 |
| Treasury stock | (19,387) | (19,387) |
| Accumulated deficit | (36,978,298) | (36,669,318) |
| Total Stockholders' Equity (Deficit) | (260,523) | (247,566) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 93,773 | $ 110,419 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) | 12 Months Ended | |
| Jun. 30, 2017 | Jun. 30, 2016 | |
| REVENUES | ||
| Product sales | $ 67,653 | $ 48,009 |
| COST OF SALES | 693 | 293 |
| GROSS MARGIN | 66,960 | 47,716 |
| OPERATING EXPENSES | ||
| Research and development | 16,530 | 37,780 |
| Professional fees | 225,901 | 145,619 |
| General and administrative | 141,328 | 225,221 |
| Total Operating Expenses | 383,759 | 408,620 |
| OPERATING LOSS | (316,799) | (360,904) |
| OTHER INCOME (EXPENSE) | ||
| Gain in change in derivative liabilities | 28,057 | |
| Amortization of debt discount | (50,000) | |
| Interest expense | (9,211) | (69,835) |
| Gain on sale of joint venture | 6,322 | |
| Loss on foreign currency exchange | (3,596) | |
| Total other income (expense) | (12,807) | (85,456) |
| Loss before income taxes and non-controlling interest | (329,606) | (446,360) |
| NET INCOME (LOSS) | (329,606) | $ (446,360) |
| Less: Net loss attributable to non-controlling interest | $ (20,626) | |
| BASIC AND DILUTED LOSS PER SHARE | $ 0 | $ 0 |
| BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 178,461,623 | 154,807,880 |
| Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
| Jun. 30, 2017 | Jun. 30, 2016 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $ (329,606) | $ (446,360) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Gain on change in derivative liability | (28,057) | |
| Amortization of deferred finance fees | 50,000 | |
| Amortization of debt discount | (50,000) | |
| Common stock issued for services | 9,620 | |
| Foreign currency transaction gain/loss | $ 3,169 | |
| Changes in operating assets and liabilities | ||
| Trade accounts receivable | 48 | (6,989) |
| Prepaid expenses and other current assets | 4,294 | 7,040 |
| Tax refunds receivable | 929 | 12,619 |
| Related party receiveables | (803) | |
| Accounts payable and accrued expenses | (14,546) | 69,683 |
| Related parties accounts payable | 3,792 | (102,693) |
| Net Cash Used in Operating Activities | (323,103) | (394,757) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from sale of interest in joint venture | 6,941 | |
| Net Cash Provided by Investing Activities | 6,941 | |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from resell of treasury stock | 22,210 | |
| Prepayment of convertible debt | (26,300) | |
| Proceeds from common stock issued | 307,590 | 432,456 |
| Net Cash Provided by Financing Activities | 307,590 | 428,366 |
| EFFECTS OF EXCHANGE RATE | 2,428 | 11,352 |
| NET INCREASE (DECREASE) IN CASH | (13,084) | 52,402 |
| CASH AT BEGINNING OF PERIOD | 70,074 | 17,672 |
| CASH AT END OF PERIOD | 56,990 | 70,074 |
| CASH PAID FOR: | ||
| Interest | $ 1,542 | 9,820 |
| NON CASH INVESTING AND FINANCING ACTIVITIES | ||
| Debt discount on convertible note and related derivative liability | $ 50,000 | |
| Conversion of debt and interest into common stock | 2647400.00% | |
| Change in derivative due to conversion | $ 21,943 | |
| Treasury stock reissued | 320,000 | |
| Forgiveness of liabilities owed to Director | $ 23,329 | |
